Follow The Filings

FATE Fate Therapeutics Inc.

Health Care, filed as FATE THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.3%
  • $1.4M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Fate Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.27%

Who owns FATE

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.27% Reduce −4.5% 525,000 $1.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FATE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FATE insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 6 sales to cover taxes, 4 option exercises, 3 stock grants, and 2 other transactions.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $63.53M $13.63M $6.65M
Net income -$160.93M -$186.26M -$136.32M
Net margin * -253.3% -1366.5% -2051.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $331.54M $291.91M $208.7M
Total non-current assets * $174.68M $148.78M $110.23M
Total assets $506.22M $440.69M $318.94M
Total current liabilities $39.09M $38.52M $36.07M
Total equity $368.42M $318.73M $207.18M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$132.26M -$122.87M -$106.08M
Cash from investing $112.66M $12.22M $111.17M
Cash from financing $0.085M $99.89M $5.49M
Net change in cash -$19.51M -$10.76M $10.57M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.